- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
After Roche, Celgene Faces Value Push-Back From NICE
After Roche saw 2 product rejects a few weeks back from NICE, based on a value argument, Celgene is in a similar boat with it's multiple myeloma drug pomalidomide.
Patients with multiple myeloma (MM) are currently unlikely to get ‘routine’ access to Celgene’s Imnovid (pomalidomide) on the National Health Service in England after cost-regulators rejected funding for the drug.
In draft guidelines, the National Institute for Health and Care Excellence said it is not recommending third-line use of Imnovid in MM patients because Celgene failed to provide sufficient evidence of its effectiveness compared with current care.
In other words, the drug did not offer “enough benefit to justify its high price,” the Institute said.
The cost per quality-adjusted life year (QALY) gained presented by the company was over £50,000 compared with Velcade bortezomib, but even higher—at more than £70,000 per QALY—when compared with bendamustine plus thalidomide and dexamethasone, falling outside the range of what is normally considered value for money.
Read the article on Pharmacy Times: http://bit.ly/1w6UIRN
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
